section name header

Introduction/Etiology/Epidemiology

Signs and Symptoms

Three patterns of infection may be observed.

Figure 37.1. Tinea Capitis. A Well-Defined Patch of Alopecia within Which are Scale, Black Dot Hairs (Yellow Arrows), and Pustules (Red Arrow).

Figure 37.2. Diffuse Scaling of the Scalp is Observed in the Seborrheic Form of Tinea Capitis.

Figure 37.3. A Kerion is a Tender, Boggy Mass Located on the Scalp.

Look-alikes

In each of the conditions listed herein, a potassium hydroxide preparation or fungal culture would fail to confirm the presence of fungal infection.

DisorderDifferentiating Features
Alopecia areata
  • Round or oval patches of alopecia that lack scaling, inflammation, or black dot hairs.

  • Nail pitting often present.

Trichotillomania
  • Often ill-defined patches of alopecia within which hairs are of differing lengths.

  • Petechiae or hemorrhagic crusts may be present if hairs pulled from the scalp.

  • Scaling and black dot hairs absent.

  • History of hair manipulation may be offered by family (but not always).

Bacterial folliculitis
  • Alopecia and scaling absent.

  • Culture positive for Staphylococcus aureus.

  • Note: In patients who have tinea capitis, S aureus often can be cultured from the scalp (although the pustules themselves may be sterile).

Bacterial abscess
  • Less likely to produce alopecia than a kerion.

  • Scaling absent.

  • Culture of contents usually reveals S aureus or other bacterial organisms.

  • Note: In patients who have tinea capitis, S aureus often can be cultured from the scalp (although the pustules themselves may be sterile).

Traction alopecia
  • Traction on hair may produce alopecia localized to areas where hair is parted.

  • Folliculitis may occur, but scaling and black dot hairs absent.

  • History of tight braids or ponytails often present, with hair thinning in peripheral zones.

Seborrheic dermatitis
  • Typically does not produce alopecia.

  • Unlikely to occur in children (most often affects infants and those at or beyond puberty).

How to Make the Diagnosis

Figure 37.4. Tinea Capitis Caused by Trichophyton Tonsurans Produces an Endothrix Infection. The Infected Black Dot Hair is Filled with Arthrospores, the Spherical Objects Shown Here.

Figure 37.5. The Diagnosis of Tinea Capitis May be Confirmed by Performing a Fungal Culture. Uninoculated Medium is Yellow (Left). Within 2 Weeks of Inoculation with Scale or Black Dot Hairs Scraped from the Scalp, There is Fungal Growth and the Medium Turns Red (Right).

Treatment

Table 37.1. Recommended Therapy for Tinea Capitis

DrugDosageDuration
Griseofulvin microsize (liquid 125 mg/5 mL)15–25 mg/kg/d (max 1 g/d)6–8 wk; continue until clinically clear

FDA approved for children 2 y

Griseofulvin ultramicrosize (tablets of varying size)10–15 mg/kg/d (max 750 mg/d)6–8 wk; continue until clinically clear

FDA approved for children 2 y

Terbinafine tablets (250 mg)

a

4–6 mg/kg/d (max 250 mg); or

10–20 kg: 62.5 mg

20–40 kg: 125 mg

>40 kg: 250 mg

Trichophyton tonsurans: 4–6 wk

Microsporum canis: 8–12 wk

Not FDA approved for the treatment of tinea capitis in children

Terbinafine granules (125 mg and 187.5 mg)

b

<25 kg: 125 mg

25–35 kg: 187.5 mg

>35 kg: 250 mg

Trichophyton tonsurans: 4–6 wk

Microsporum canis: 8–12 wk

FDA approved for children 4 y

Fluconazole

c

(liquid 10 mg/mL, 40 mg/mL; tablet 50 mg, 100 mg, 150 mg, and 200 mg)
6 mg/kg/d (max 400 mg/d)3–6 wk depending on severity

Not FDA approved for the treatment of tinea capitis in children

Itraconazole solution

c

(10 mg/mL)
3 mg/kg/d (max 600 mg/d)2–4 wk or longer, depending on severity

Not FDA approved for the treatment of tinea capitis in children

Itraconazole capsule (65 mg, 100 mg)5 mg/kg/d (max 600 mg/d)2–4 wk or longer, depending on severity

Not FDA approved for the treatment of tinea capitis in children

Abbreviations: FDA, US Food and Drug Administration; max, maximum.

Some experts use “higher” dosing listed for terbinafine granules instead.

Terbinafine granules have been discontinued in the in the United States.

See Red Book: 2024–2027 Report of the Committee on Infectious Diseases Antifungal Drugs for Systemic Fungal Infections and Recommended Doses of Parenteral and Oral Antifungal Drugs, for adverse reactions and therapeutic drug monitoring recommendations.

From American Academy of Pediatrics. Tinea capitis. In: Kimberlin DW, Banerjee R, Barnett ED, et al, eds. Red Book: 2024–2027 Report of the Committee on Infectious Diseases. 33rd. American Academy of Pediatrics; 2024:854–858.

Treating Associated Conditions

Prognosis

When to Worry or Refer

Resources for Families